Activated platelets stimulate effector CD8+ T cells to enhance HNSCC immunotherapy efficacy

Area of Science:

• Immunology
• Oncology
• Hematology

Background:

• Programmed Death Receptor-1 (PD-1) inhibitors are crucial in cancer immunotherapy.
• Platelets, traditionally known for hemostasis, are increasingly recognized for their role in cancer immunity.
• Understanding platelet-immune cell interactions is key for novel cancer therapies.

Purpose of the Study:

• To investigate the relationship between pre-treatment immune cell states and platelet activation with PD-1 inhibitor efficacy.
• To identify potential predictive biomarkers for immunotherapy response in head and neck cancer.

Main Methods:

• Analysis of peripheral blood mononuclear cells (PBMCs) and platelet activation markers.
• Comparison of immune cell profiles and platelet status between responsive and non-responsive cancer patients.

Main Results:

• Patients with better treatment responses showed higher pre-treatment levels of mature and activated CD8+ T cells.
• Increased platelet activation was observed in responsive patients, potentially modulating immune cells.
• Responsive patients had a higher abundance of activated effector CD8+ T cells post-immunotherapy.

Conclusions:

• Pre-treatment CD8+ T cell status and platelet activation levels may predict PD-1 inhibitor efficacy in head and neck cancer.
• Activated platelets may promote CD8+ effector memory T cell maturation and function.
• These findings offer insights into immune cell-platelet interactions and potential immunotherapy optimization strategies.